Importance of species selection in drug toxicity testing

Toxicology Letters

Volumn 102-103, Issue , 1998, Pages 545-550

  Morton, Douglas M ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Drug disposition; Metabolic profile; Species selection

Indexed keywords

BROMOCRIPTINE; CHLORPROMAZINE; SALBUTAMOL; SULFAMETHOXAZOLE;

ANIMAL MODEL; CARCINOGEN TESTING; CONFERENCE PAPER; CONTROLLED STUDY; DRUG METABOLISM; DRUG SCREENING; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RISK ASSESSMENT; SPECIES DIFFERENCE; STRAIN DIFFERENCE; TOXICOLOGY;

ANIMALS; ARABINOFURANOSYLURACIL; HUMANS; PHARMACOKINETICS; SPECIES SPECIFICITY; TOXICOLOGY;

ANIMALIA; RODENTIA;

EID: 4243813744     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4274(98)00263-X     Document Type: Conference Paper

References (9)

1. Gold, L.S., Bernstein, L., Magaw, R., Slone, T.H., 1989. Interspecies extrapolation in carcinogenesis: prediction between rats and mice. Environ. Health Perspect. 81, 211-219.
2. Haseman, J.K., Huff, J.E., Zeiger, E., McConnell, E.E., 1987. Comparative results of 327 chemical carcinogenicity studies. Environ. Health Perspect. 74, 229-235.
3. Hottendorf, G.H., 1987. Progress in Drug Research, vol. 31.
4. International Conference on Harmonization Guidelines Topic S1B Step 4, 1997. Testing for Carcinogenicity in Pharmaceuticals.
5. Kleiner, D.E., Gaffey, M.J., Sallie, R., et al., 1997. Histopathologic changes associated with fialuridine hepatotoxicity. Mod. Pathol. 10, 192-199.
6. McKenzie, R., Fried, M.W., Sallie, R., et al., 1995. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N. Engl. J. Med. 333, 1099-1105.
7. Richardson, F.C., Engelhardt, J.A., Bowsher, R.R., 1994. Fialuridine accumulates in DNA of dogs, monkeys, and rats following long-term oral administration. Pharmacology 91, 12003-12007.
8. Ryffel, B., 1996. Predictive value of carcinogenicity studies for protein and gene therapy. In: Carcinogenicity Testing of Potential Medicines-Challenges and Changes. IBC Technical Services, London.
9. Tennant, B.C., Baldwin, B.H., Graham, L.A., et al., 1998. Antiviral activity and toxicity of fialuridine in the wood-chuck model of hepatitis B virus infection. Hepatology 28, 179-191.